About servier

About Servier
– Backgrounder –
Servier is France’s leading independent pharmaceutical company and the country’s second largest drug company. Servier is present in 140 countries worldwide. R&D at Servier spans a range of therapeutic fields, with the main areas of focus being cardiovascular disease, neuroscience, oncology, metabolic disorders, and rheumatology. In the field of cardiovascular disease in particular, Servier is one of the principal research organizations dedicated to the development of new medicines. Cardiovascular commitment
Servier has a long-standing interest in the field of cardiovascular disease. Nearly two thirds (63%) of Servier’s global turnover from medicines is made up of drugs targeted at cardiovascular diseases. Servier is unique among global pharmaceutical companies in that all the company’s cardiovascular products it has introduced have stemmed from its own research efforts.
Procoralan* (ivabradine) is the first and only specific and selective If current inhibitor of the sinus node.
Procoralan was approved in 2005 by the European regulatory authorities (EMEA) for clinical use in
selected patients with chronic stable angina. It is currently available in around 70 countries worldwide. Servier’s cardiovascular portfolio also includes Coversyl® (perindopril), Servier’s leading product for
high blood pressure, heart failure, and for the treatment of patients with stable coronary artery disease (CAD) to reduce the risk of coronary events, Vastarel MR® (trimetazidine) for stable angina and
Preterax® (perindopril / indapamide) and Natrilix® SR (indapamide) for hypertension.
Servier and landmark clinical trials
Servier has been involved in several large-scale outcomes clinical trials for several years including the BEAUTIFUL (MorBidity-mortality EvAlUaTion of the If Inhibitor ivabradine in patients with coronary
disease and left ventricULar dysfunction) trial, which demonstrated the benefits of Procoralan
(ivabradine) in reducing cardiovascular events in patients with coronary artery disease (CAD) receiving current preventative therapy . The results of this trial have major implications for the management of Other Servier trials include the ADVANCE (Action in Diabetes and Vascular Disease: PreterAx and
DiamicroN MR Controlled Evaluation) study. This is the world’s largest prospective mortality/morbidity
trial in patients with type 2 diabetes to date. The study demonstrated the effects of blood pressure lowering with Preterax®-based therapy1 and intensive glucose-lowering with Diamicron MR-based therapy2 on the risk of complications in patients with type 2 diabetes.1 The efficacy of perindopril alone and in combination has been investigated in a number of trials. The
PROGRESS (Perindopril prOtection aGainst REcurrent Stroke Study) showed that perindopril 4 mg +
indapamide 2.5 mg reduced the risk of stroke by 29% in patients with a history of cerebrovascular The EUROPA study (European trial on Reduction Of cardiac events with Perindopril in stable coronary
Artery disease) showed that perindopril 8 mg is associated with a 20% reduction in the risk of
cardiovascular death, myocardial infarction, and cardiac arrest compared with placebo in patients with Other significant, independent, investigator-led trials include ASCOT-BPLA5 in hypertension (amlodipine
+ perindopril), PREAMI6 in postmyocardial infarction in elderly (perindopril) and PEP-CHF7 in diastolic
*Depending on the country, ivabradine is available as Procoralan®, Coralan®, Coraxan®, or Corlentor®


1. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 ; 370 : 829-40. 2. ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358 : 2560-72. 3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033-41. 4. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 ; 362 : 762-68. 5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 ; 6. The PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodelling and clinical outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med. 2006 ; 166 : 659-66. 7. PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006 ;

Source: http://www.beautiful-study.com/static/html/download/About_Servier.pdf

The disease pattern in mountain village

THE DISEASE PATTERN IN AN ‘UNREACHED’ MOUNTAIN VILLAGE *Department of Anatomy, University of Jos**Department of Medical Microbiology, University of***C/O Department of Obstetrics and Gynaecology,Polokwane Mankweng Hospital Complex, Pietersburg,Keywords: Unreached people group, Tagir Zangam,This project was carried out under a Medical mission byThis work was conducted on a mountain


Journal of Veterinary Emergency and Critical Care 17(1) 2007, pp 61–66Comparison of the hypothalamic^pituitary^adrenalaxis in MDR1-1 D and MDR1 wildtype dogsKatrina L. Mealey, DVM, PhD, DACVIM, DACVCP, John M. Gay, DVM, PhD, DACVPM,Linda G. Martin, DVM, MS, DACVECC and Denise K. Waiting, LVTObjective: To evaluate the hypothalamic–pituitary–adrenal (HPA) axis in MDR1-1D (dogs with the MDR

Copyright © 2010-2014 Drug Shortages pdf